Kostares Evangelos, Kostare Georgia, Kostares Michael, Pitsigavdaki Fani, Kyrgidis Athanassios, Perisanidis Christos, Kantzanou Maria
Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 115 27 Athens, Greece.
Department of Anatomy, Medical School, National and Kapodistrian University of Athens, 115 27 Athens, Greece.
Clin Pract. 2025 Aug 14;15(8):151. doi: 10.3390/clinpract15080151.
: Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication in patients treated with antiresorptive or antiangiogenic agents, particularly those with cancer-related comorbidities. This systematic review and meta-analysis aimed to estimate the prevalence of free flap failure in patients undergoing microvascular reconstruction for MRONJ. : A comprehensive literature search was conducted across Medline/PubMed, Scopus, and Web of Science up to 30 January 2025. Inclusion criteria were observational studies involving MRONJ patients treated with free flap reconstruction. Risk of bias was assessed using the Newcastle-Ottawa Scale. The pooled prevalence of free flap failure was calculated using a random-effects model with Freeman-Tukey double arcsine transformation. : Twelve studies were included in the quantitative analysis. The fibula free flap was the most frequently used flap. The pooled prevalence of free flap failure was 0.1% (95% CI: 0-2.3%), with no significant associations observed in meta-regression analyses for publication year, patient age, or sex. All included studies were of moderate methodological quality. : These findings suggest that free flap reconstruction is a reliable and effective surgical option for managing advanced MRONJ in well-resourced and specialized healthcare settings; however, limitations such as small sample sizes and heterogeneity in protocols must be considered. Further high-quality, multicenter studies are needed to evaluate long-term outcomes and refine perioperative management strategies.
颌骨药物相关性骨坏死(MRONJ)是接受抗吸收或抗血管生成药物治疗的患者,尤其是患有癌症相关合并症患者的一种严重并发症。本系统评价和荟萃分析旨在估计接受微血管重建治疗MRONJ患者的游离皮瓣失败率。:截至2025年1月30日,在Medline/PubMed、Scopus和Web of Science上进行了全面的文献检索。纳入标准为涉及接受游离皮瓣重建治疗的MRONJ患者的观察性研究。使用纽卡斯尔-渥太华量表评估偏倚风险。使用Freeman-Tukey双反正弦变换的随机效应模型计算游离皮瓣失败的合并患病率。:十二项研究纳入定量分析。腓骨游离皮瓣是最常用的皮瓣。游离皮瓣失败的合并患病率为0.1%(95%CI:0-2.3%),在按发表年份、患者年龄或性别进行的荟萃回归分析中未观察到显著关联。所有纳入研究的方法学质量中等。:这些发现表明,在资源丰富和专业的医疗环境中,游离皮瓣重建是治疗晚期MRONJ的可靠且有效的手术选择;然而,必须考虑样本量小和方案异质性等局限性。需要进一步开展高质量、多中心研究来评估长期结局并完善围手术期管理策略。